Free Trial
NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Mineralys Therapeutics logo
$15.22 +0.01 (+0.07%)
Closing price 04:00 PM Eastern
Extended Trading
$15.22 -0.01 (-0.03%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Key Stats

Today's Range
$15.16
$15.79
50-Day Range
$12.87
$15.48
52-Week Range
$8.24
$18.38
Volume
761,290 shs
Average Volume
928,404 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.40
Consensus Rating
Moderate Buy

Company Overview

Mineralys Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

MLYS MarketRank™: 

Mineralys Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 364th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mineralys Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mineralys Therapeutics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mineralys Therapeutics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mineralys Therapeutics has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mineralys Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.19% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently decreased by 11.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mineralys Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mineralys Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.19% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently decreased by 11.05%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mineralys Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Mineralys Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,776,262.00 in company stock.

  • Percentage Held by Insiders

    25.56% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mineralys Therapeutics' insider trading history.
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MLYS Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
HC Wainwright Has Positive Forecast for MLYS Q3 Earnings
See More Headlines

MLYS Stock Analysis - Frequently Asked Questions

Mineralys Therapeutics' stock was trading at $12.31 at the beginning of the year. Since then, MLYS shares have increased by 23.6% and is now trading at $15.22.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its earnings results on Tuesday, August, 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.12.
Read the conference call transcript
.

Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share.

Top institutional shareholders of Mineralys Therapeutics include Franklin Resources Inc. (2.77%), Jennison Associates LLC (1.90%), Geode Capital Management LLC (1.46%) and American Century Companies Inc. (1.28%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman.
View institutional ownership trends
.

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/12/2025
Today
8/28/2025
Next Earnings (Estimated)
11/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLYS
CIK
1933414
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$15.00
Potential Upside/Downside
+121.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$177.81 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-70.44%
Return on Assets
-65.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.12
Quick Ratio
15.12

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.73 per share
Price / Book
3.28

Miscellaneous

Outstanding Shares
66,290,000
Free Float
49,350,000
Market Cap
$1.03 billion
Optionable
Optionable
Beta
-0.29
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:MLYS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners